Pharmacologic Basis for the Safety Assessment of Recombinant Human Proteins

1. Young, F.E. (1987). An international framework for biotechnology regulation. Pharmacol. Tech. October. 16-18.

2. Maheshwara, R.K. , Czarniecki, C. , Dutta, G.P. , Puri, S.K. , Dhawan, B.N. , and Friedman, R. M. (1986). Recombinant human gamma interferon inhibits simian malaria. Infect. Immun. 53, 628–630.

3. Schellekens, H. , Dereus, A. , and Meide, P. H. (1984). The chimpanzee as a odel to test the side effects of human interferons. J. Med. Primatol. 13, 235–245.

4. Hendrickx, A.G. , and Cukierski, M. A. (1987) Reproductive and developmental toxlcology in nonhuman primates. In: Preclinical Safety, of Biotechnology Products for Human Use. New York: Alan R. Liss, pp. 73–88

5. Palladino, M.A. , and Finkle, B. S. (1986). Immunopharmacology of tumor necrosis factors a and b. Tips 7, 162–164.

6. Fransen, L. , Ruysschaert, M.-R. , Van Der Heyden, J. , and Fiers, W. (1986). Recombinant tumor necrosis factor: Species specificity for a variety of human and murine transformed cell lines. Cell. Immunol. 100, 260–267.

7. Kramer, S.K. , Aggarwal, B.A. , Eessalu, T.E. , Mccabe, S.M. , Ferraiolo, B.L. , Figari, I.S. , and Palladino, M. A. (1988). Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res. 48, 920–925.

8. Shalaby, M.R. , Hamilton, E.B. , Benninger, A.H. , and Marafino, B. J. (1985). In vivo anti-viral activity of recombinant murine gamma interferon. J. Interferon Res. 5, 339–345.

9. Chawla, R.K. , Parks, J.S. , and Rudman, D. (1983). Structural variants of human growth hormone: Biochemical, genetic and clinical aspects. Annu. Rev. Med. 34, 519–547.

10. Wilhelmi, A.E. (1975). Chemistry of growth hormone. In: Greep, R.O. , and Astwood, E.B. , eds. Handbook of Physiology, Vol 4. Washington, D.C.: American Physiolical Society, pp. 59–78

11. Collen, D. , Stassen, J.M. , and Verstraete, M. (1983). Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. J. Clin Invest. 71, 368–376.

12. Gold, H.K. , Fallon, J.T. , Yasuda, T. , Leinbach, R.C. , Khaw, B.A. , Newell, J.B. , Guerrero, J.L. , Vislosky, F.M. , Hoyng, C.F. , Grossbard, E. , and Collen, E. (1984). Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 70, 700–707.

13. Korninger, C. , and Collen, D. (1981). Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 46, 561–565.

14. Lijnen, H.R. , Marafino, B.J. , and Collen, D. (1984). In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species. Thromb. Haemostas. 52, 308–310.

15. Hotchkiss, A. , Refino, C. , Deguzman, L. , Rigter, B. , and Eisert, W. (1987). A new pan species model for the measurement of in vivo thrombolysis. Thromb. Haemostas. 58, 107.

16. Donahue, R.E. , Wang, E.A. , Kaufman, R.J. , Foutch, L. , Leary, A.C. , Witek-Giannetti, J.S. , Metzger, M. , Hewick, R.M. , Steinbrink, D.R. , Shaw, G. , Kamen, R. , and Clark, S.C. , (1986). Effects of N-linked carbohydrate on the in vivo properties of human Gm-Csf. Cold Spring Harbor Symp. Quant. Biol. 51, 685–692.

17. Ferraiolo, B.L. , Moore, J.A. , Crase, D. , Gribling, P. , Wilking, H. , and Baughman, R. A. (1988). Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Drug Metab. Dispos. 16, 270–275.